



We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious diseases and other indications of unmet patient need:

Oncology



Infectious Diseases



- FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.
- 2 A member of the Roche group
- 3 Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with ICI+/- chemotherapy 4 Small Molecule Immunomodulators.

- 5 BioNTech holds the commercialization license in Türkiye and Germany as part of the collaboration with Pfizer.
 6 The COVID-19-Influenza combination is a Phase 1 trial in partnership with Pfizer. Further development is subject to reaching agreement.
 7 BioNTech holds worldwide distribution rights except developing countries where Bill & Melinda Gates Foundation holds distribution rights.
 8 Coalition for Epidemic Preparedness Innovations